July 22, 2021 5:14 AM PDT
Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market, 2021-2030.”
The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:
- A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
- Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
- A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
- A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
- A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
- A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
- An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
- A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
- An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
- An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
- A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
- A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
- A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
- A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
Request for Customization: https://www.rootsanalysis.com/reports/250/request-customization.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Commonly Outsourced Business Operations
- Active Pharmaceutical Ingredients (API)
- Finished Dosage Formulations (FDF)
Types of Expression System
- Mammalian
- Microbial
- Others
Company Size
- Small
- Mid-Sized
- Large and Very Large
Scale of Operation
- Preclinical
- Clinical
- Commercial
Key Geographical Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
The report also features detailed transcripts of discussions held with the following experts:
- Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
- Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
- Christian Bailly, Director of CDMO, Pierre Fabre
- Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
- David C Cunningham, Director Corporate Development, Goodwin Biotechnology
- Dietmar Katinger, Chief Executive Officer, Polymun Scientific
- Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
- Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
- Kevin Daley, Director Pharmaceuticals, Novasep
- Mark Wright, Site Head, Grangemouth, Piramal Healthcare
- Nicolas Grandchamp, R&D Leader, GEG Tech
- Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
- Sebastian Schuck, Head of Business Development, Wacker Biotech
- Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
- Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
- Tim Oldham, Chief Executive Officer, Cell Therapies
Key companies covered in the report
- 3P Biopharmaceuticals
- Abzena
- Albany Molecular Research
- BioVectra
- BioXcellence (Boehringer Ingelheim)
- Celonic
- Charles River Laboratories
- ChemPartner
- Cobra Biologics
- CordenPharma
- Cytovance Biologics
- GE Healthcare
- Goodwin Biotechnology
- Grand River Aseptic Manufacturing
- IDT Biologika
- KBI BioPharma
- Kemwell Biopharma
- LFB Biomanufacturing
- Meridian Life Science
- Patheon
- Pfizer CentreOne
- PX'Therapeutics
- Samsung BioLogics
- Sanofi, CEPiA
- Thermo Fisher Scientific
- Vetter Pharma International
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/250/request-sample.html
Also Visit Our Latest Publication:
Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market
CAR-T Cell Therapies Market
Patient Recruitment and Retention Services Market
mRNA Therapeutics and Vaccines Market
T-Cell (CAR-T, TCR, and TIL) Therapies Market
Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market, 2021-2030.”
The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:
- A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
- Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
- A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
- A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
- A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
- A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
- An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
- A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
- An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
- An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
- A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
- A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
- A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
- A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
Request for Customization: https://www.rootsanalysis.com/reports/250/request-customization.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Commonly Outsourced Business Operations
- Active Pharmaceutical Ingredients (API)
- Finished Dosage Formulations (FDF)
Types of Expression System
- Mammalian
- Microbial
- Others
Company Size
- Small
- Mid-Sized
- Large and Very Large
Scale of Operation
- Preclinical
- Clinical
- Commercial
Key Geographical Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
The report also features detailed transcripts of discussions held with the following experts:
- Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
- Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
- Christian Bailly, Director of CDMO, Pierre Fabre
- Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
- David C Cunningham, Director Corporate Development, Goodwin Biotechnology
- Dietmar Katinger, Chief Executive Officer, Polymun Scientific
- Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
- Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
- Kevin Daley, Director Pharmaceuticals, Novasep
- Mark Wright, Site Head, Grangemouth, Piramal Healthcare
- Nicolas Grandchamp, R&D Leader, GEG Tech
- Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
- Sebastian Schuck, Head of Business Development, Wacker Biotech
- Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
- Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
- Tim Oldham, Chief Executive Officer, Cell Therapies
Key companies covered in the report
- 3P Biopharmaceuticals
- Abzena
- Albany Molecular Research
- BioVectra
- BioXcellence (Boehringer Ingelheim)
- Celonic
- Charles River Laboratories
- ChemPartner
- Cobra Biologics
- CordenPharma
- Cytovance Biologics
- GE Healthcare
- Goodwin Biotechnology
- Grand River Aseptic Manufacturing
- IDT Biologika
- KBI BioPharma
- Kemwell Biopharma
- LFB Biomanufacturing
- Meridian Life Science
- Patheon
- Pfizer CentreOne
- PX'Therapeutics
- Samsung BioLogics
- Sanofi, CEPiA
- Thermo Fisher Scientific
- Vetter Pharma International
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/250/request-sample.html
Also Visit Our Latest Publication:
Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market
CAR-T Cell Therapies Market
Patient Recruitment and Retention Services Market
mRNA Therapeutics and Vaccines Market
T-Cell (CAR-T, TCR, and TIL) Therapies Market